Erez Aminov, CEO & Chairman of the Board, and Dr. Itzchak Angel, Chief Scientific Advisor for MIRA Prescription drugs MIRA, had been not too long ago interviewed by Benzinga.
MIRA is a pre-clinical biopharma centered on growing therapies for neurologic and neuropsychiatric problems. It holds unique rights to Ketamir-2, an oral ketamine analog being studied for neuropathic ache, treatment-resistant despair, main depressive dysfunction with suicidal ideation and PTSD.
The corporate’s different major asset, MIRA-55, is a novel pharmaceutical marijuana analog that would present enhanced therapeutic results over THC.
Watch the complete interview right here:
Featured picture by Jeremy Bishop on Unsplash.
This publish comprises sponsored content material. This content material is for informational functions solely and isn’t meant to be investing recommendation.
Market Information and Information dropped at you by Benzinga APIs
© 2024 Benzinga.com. Benzinga doesn’t present funding recommendation. All rights reserved.
